Potential biomarker of metformin action

Ling He, Shumei Meng, Emily L. Germain-Lee, Sally Radovick, Fredric E. Wondisford

Research output: Contribution to journalArticle

Abstract

Metformin is a first-line, anti-diabetic agent prescribed to over 150 million people worldwide. The main effect of metformin is to suppress glucose production in the liver; however, there is no reliable biomarker to assess the effectiveness of metformin administration. Our previous studies have shown that phosphorylation of CBP at S436 is important for the regulation of hepatic glucose production by metformin. In current study, we found that CBP could be phosphorylated in white blood cells (WBCs), and CBP phosphorylation in the liver and in WBCs of mice had a similar pattern of change during a fasting time course experiment. These data suggests that CBP phosphorylation in WBCs may be used as a biomarker of metformin action in the liver.

Original languageEnglish (US)
Pages (from-to)363-369
Number of pages7
JournalJournal of Endocrinology
Volume221
Issue number3
DOIs
StatePublished - Jun 2014

Keywords

  • Diabetes
  • Glucose metabolism
  • Liver
  • Metabolism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Potential biomarker of metformin action'. Together they form a unique fingerprint.

  • Cite this

    He, L., Meng, S., Germain-Lee, E. L., Radovick, S., & Wondisford, F. E. (2014). Potential biomarker of metformin action. Journal of Endocrinology, 221(3), 363-369. https://doi.org/10.1530/JOE-14-0084